Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04201873Phase 1Active Not Recruiting

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Role: collaborator

NCT04299113Phase 1Active Not Recruiting

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Role: collaborator

NCT06535828Withdrawn

AIM4 AI and Mechanistic Modeling in Molecular Medicine

Role: collaborator

NCT01811992Phase 1Completed

Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma

Role: collaborator

NCT04299620Not ApplicableActive Not Recruiting

Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy

Role: collaborator

All 5 trials loaded